Revolution Medicines reported daraxonrasib produced a 47% objective response rate (ORR) in a treatment‑naïve cohort of RAS‑mutant metastatic pancreatic ductal adenocarcinoma (PDAC), prompting plans to advance toward a Phase 3 trial. Company data presented in investor materials showed disease control rates near 89% and a generally favorable safety profile versus historical chemotherapy benchmarks. The data suggest a possible chemotherapy‑sparing option for a tumor type dominated by cytotoxic regimens and could reshape RAS‑targeted development strategies.